Skip to main content
Top
Published in: BMC Cancer 1/2020

Open Access 01-12-2020 | Case report

Primary malignant pericardial tumour in Lynch syndrome

Authors: Pasquale Paolisso, Giulia Saturi, Alberto Foà, Maristella Saponara, Margherita Nannini, Maria Abbondanza Pantaleo, Ornella Leone, Daniela Turchetti, Daniele Calistri, Carlo Savini, Davide Pacini, Carmine Pizzi, Nazzareno Galiè

Published in: BMC Cancer | Issue 1/2020

Login to get access

Abstract

Background

This case represents the first report of malignant primary cardiac tumour in a patient with Lynch Syndrome associated with MSH2 pathogenic variant.

Case presentation

A 57-year-old woman with previous ovarian cystadenocarcinoma was admitted to the emergency room for hematic pericardial effusion. Multimodal diagnostic imaging revealed two solid pericardial vascularized masses. After pericardiectomy, the final histological diagnosis was poorly differentiated pleomorphic sarcomatoid carcinoma. During follow-up she developed an ampulla of Vater adenocarcinoma. Genetic analysis identified an MSH2 pathogenic variant.

Conclusion

This case contributes to expand the tumour spectrum of Lynch syndrome, suggesting that MSH2 pathogenic variants cause a more complex multi-tumour cancer syndrome than the classic Lynch Syndrome. In MSH2 variant carriers, symptoms such as dyspnoea and chest discomfort might alert for rare tumours and a focused cardiac evaluation should be considered.
Literature
9.
go back to reference Lam KY, Dickens P, Chan AC. Tumors of the heart: a 20-year experience with a review of 12,485 consecutive autopsies. Arch Pathol Lab Med. 1993;117:1027–31.PubMed Lam KY, Dickens P, Chan AC. Tumors of the heart: a 20-year experience with a review of 12,485 consecutive autopsies. Arch Pathol Lab Med. 1993;117:1027–31.PubMed
Metadata
Title
Primary malignant pericardial tumour in Lynch syndrome
Authors
Pasquale Paolisso
Giulia Saturi
Alberto Foà
Maristella Saponara
Margherita Nannini
Maria Abbondanza Pantaleo
Ornella Leone
Daniela Turchetti
Daniele Calistri
Carlo Savini
Davide Pacini
Carmine Pizzi
Nazzareno Galiè
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-6677-y

Other articles of this Issue 1/2020

BMC Cancer 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine